Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ARS Pharmaceuticals Inc shares valued at $592,570 were sold by Chakma Justin on Nov 26 ’24. At $14.05 per share, Chakma Justin sold 42,186 shares. The insider’s holdings dropped to 161,380 shares worth approximately $2.34 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Chakma Justin sold 32,814 shares, netting a total of over 459,422 in proceeds. Following the sale of shares at $14.00 each, the insider now holds 203,566 shares.
Before that, Chakma Justin had sold 25,000 shares from its account. In a trade valued at $359,750, the Chief Business Officer traded ARS Pharmaceuticals Inc shares for $14.39 each. Upon closing the transaction, the insider’s holdings decreased to 25,000 shares, worth approximately $1.98 million.
As published in their initiating research note from Cantor Fitzgerald on August 20, 2024, ARS Pharmaceuticals Inc [SPRY] has been an Overweight. Analysts at Raymond James upgraded the stock from ‘”an Outperform”‘ to ‘”a Strong buy”‘ outlook in a report released in mid August. As of August 12, 2024, Leerink Partners has reiterated its “an Outperform” rating for SPRY. Earlier on July 25, 2024, Raymond James initiated its rating. Their recommendation was “an Outperform” for SPRY stock.
Analyzing SPRY Stock Performance
During the last five days, there has been a surge of approximately 7.23%. Over the course of the year, ARS Pharmaceuticals Inc shares have jumped approximately 165.15%. Shares of the company reached a 52-week high of $18.51 on 11/11/24 and a 52-week low of $5.19 on 01/04/24. A 50-day SMA is recorded $14.83, while a 200-day SMA reached $11.07. Nevertheless, trading volume fell to 0.67 million shares from 1.34 million shares the previous day.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
According to the 24-hour chart, there is a support level at 14.16, which, if violated, would cause prices to drop to 13.80. In the upper region, resistance lies at 14.90. The next price resistance is at 15.27. RSI (Relative Strength Index) is 49.29 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.40, which suggests the price will decrease in the coming days. Percent R is at 72.36%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
